Wegovy Q3 sales total $2.5 bln Beat forecast but group sales weaker than expected Results soothe investor worries over slowing obesity drug demand Shares rose nearly 9%, but later reversed course ...

Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a massive 79% in the third quarter, in a relief to investors after disappointing results three months ago. GLP-1 agonist Wegovy ...

Also Read: Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug Insulin sales increased by 10% at CER to 12.51 billion Danish kroner, and rare disease sales increased by 17% at CER ...

Wegovy sales soared 81% YoY to DKK17.3 billion; Obesity care grew 55%, while insulin sales rose 10%, boosting overall portfolio strength. The global sales increased 21% year over year (up 23% at ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Novo Nordisk (NVO) reported mixed earnings for the third quarter of 2024 but beat Wall Street revenue expectations for its blockbuster weight-loss drug, Wegovy. Novo announced an earnings per ...

Novo's drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide—while adding great heft to Denmark's economy. We travel to the Baltic to see how a ...

COPENHAGEN (Reuters) - Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.

Sales of Wegovy were 79% higher in the third quarter of 2024 compared to the same time period a year earlier, Novo Nordisk said. Novo Nordisk on Wednesday reported a third-quarter beat on sales of ...

Novo Nordisk Lifts Curbs on Wegovy Prescriptions in the U.S., Says CEO COPENHAGEN (Reuters) - Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...